Bartos1976 Posted - 23 hours ago

$CMRX wow into the 80’s. A reflection of the market or options of 200k shares to new exmployees? Will add more

johnkimble Posted - 2 days ago

$CMRX we are taking a look here it seems interesting to buy

Stock_Titan Posted - 2 days ago

$CMRX Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) https://www.stocktitan.net/news/CMRX/chimerix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-ezf8n6k43tx6.html

lizquita Posted - 3 days ago

$CMRX how this is under $1? Jeez

Bartos1976 Posted - 4 days ago

$CMRX finally averaged down

ARDX_Bull Posted - 1 week ago

$CMRX “If we really believe that there are no other therapeutic alternatives, then there will be obviously some degree of flexibility,” Pazdur said. “When we do see, however, that there may be accelerated approval with the same class of drugs with the same diseases and with sponsors previously having most of the confirmatory study accrual already completed at the time of accelerated approval, we have to have a level playing field for all of the pharmaceutical companies.” Pragmatica-Lung represents just one way to run these as Pazdur emphasized a potential “spectrum of pragmatic trials.” Such a simplified trial could only collect safety data on 20% of the patients and only grade 3 or above toxicities, and it could look at when people start new therapies as an endpoint, Pazdur said. “So I challenge you to come and meet with us to discuss these statistical designs,” Pazdur said. “And we are interested in pragmatic trials.” https://www.fiercebiotech.com/biotech/we-have-have-level-playing-field-fda-oncology-chief-explains-confirmatory-trial-rejection

SomePoorGuy Posted - 2 weeks ago

$CMRX If the Phase 3 results match the early Phase studies, this will be a success. For the sake of the patients and their families, I hope results exceed expectations.

Maxim89 Posted - 2 weeks ago

$CMRX The company has a strong financial position with over $200 million in assets and a runway of 2+ years, making it an attractive investment for those with a longer-term outlook.

Maxim89 Posted - 2 weeks ago

$CMRX The most undervalued stock in the market is this one...

Maxim89 Posted - 2 weeks ago

$CMRX

frontiere Posted - 2 weeks ago

$CMRX 2 publications from 2024: 1. https://pubmed.ncbi.nlm.nih.gov/38554031/ The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models 2. https://ascopubs.org/doi/10.1200/JCO.23.01134 ONC201 monotherapy was well tolerated and exhibited durable and clinically meaningful efficacy in recurrent H3 K27M–mutant DMG.

Mcalves Posted - 2 weeks ago

$CMRX It’s fighting to get out of this channel.

frontiere Posted - 03/31/24

$CMRX 8 of 8 screenshots by Gamber

frontiere Posted - 03/31/24

$CMRX 7 of 8 screenshots by Gamber

frontiere Posted - 03/31/24

$CMRX 6 of 8 screenshots by Gamber

frontiere Posted - 03/31/24

$CMRX 5 of 8 screenshots by Gamber

frontiere Posted - 03/31/24

$CMRX 4 of 8 screenshots by Gamber

frontiere Posted - 03/31/24

$CMRX 3 of 8 screenshots by Gamber

frontiere Posted - 03/31/24

$CMRX 2 of 8 screenshots by Gamber

frontiere Posted - 03/31/24

$CMRX (cont’d) ROW opportunities could add to that or provide non-dilutive capital. 6: Dopamine-secreting tumors could provide label expansion opportunities for dordaviprone (ONC201). 7: A second pipeline candidate, ONC206, is in dose escalation studies looking at tumors outside of the H3 K27M-mutant space. 8: The current valuation is not pricing in any further royalties from Emergent Biosciences for their legacy antiviral that was outlicensed. /end - begin text screenshots

frontiere Posted - 03/31/24

$CMRX last week one of my fave Twtr follows Matthew Gamber sent out an excellent write up on Chimerix ‘s deep value proposition. Here’s copy-paste: The crux of my thesis revolves around eight main points: Point 1: Dordaviprone (ONC201) has been tested in multiple single arm studies in both the front-line and recurrent settings with overall survival results exceeding natural disease history. 2: The Phase 3 study will have an arm doubling the dosing regimen from Phase 2 due to Project Optimus suggestions and it’s possible the drug was under-dosed in previous studies. 3: By running a Phase 3 in the frontline setting, Chimerix has maximized their chances of clinical and commercial success. 4: Dordaviprone has repeatedly shown monotherapy activity in at least 20% of recurrent patients with deep responses. 5: 2,000 U.S. patients with no approved standard of care could provide peak sales greater than $400m per year at “orphan oncology” pricing,

Smolik Posted - 03/29/24

$CMRX this is one of the weirdest price movements Ive seen in a while

Bartos1976 Posted - 03/28/24

$CMRX typical, 12% increase since. Sure there’ll be other opportunities to add below 1 again

johnkimble Posted - 03/28/24

$CMRX nice 50 day MA cross of the 200 day MA

PortfolioMgmt23 Posted - 03/28/24

$GMDAQ Clearly, I'm a fucking idiot because I just got my clocked cleaned swinging for the fences. That said, you may want to do some due diligence in $CMRX. Institutional holdings have grown in the last few months considerably. They have the only treatment that works for Midline Glioma's and are in a phase 3 that should wrap by 2026 w/ toplines due in early 2025. The phase 2's were so indepth they were trying to get an early approval but when congress pulled the FDA back on those, these guys took it in the teeth. They cash to last into 2027 and I truly believe they get a rolling submission for ONC-201 on the results of toplines. ONC-201 is SUPER well known and regarded so commercialization should be a low bar to clear. I'm crushed today, I know others are as well. I think this can 10x and I've spent a lot of time w. you guys so I hope it helps. It's all I can do right now not to help my wife cash in the NW Mutual policies, I can't be that wrong twice. Stay in touch folks.

Mcalves Posted - 03/28/24

$CMRX I will feel better when we break out if this channel or bear flag.

Smolik Posted - 03/28/24

$CMRX

Maxim89 Posted - 03/28/24

$CMRX Back to $1.25 in no time

johnkimble Posted - 03/27/24

$CMRX back over $1.30 soon enough

Mcalves Posted - 03/27/24

$CMRX buy and hold people buy and hold. No paper hands.